Trinity Biotech Gains WHO Approval for Outsourced HIV Test Manufacturing

An announcement from Trinity Biotech ( (TRIB) ) is now available.

On June 24, 2025, Trinity Biotech announced it received World Health Organization (WHO) approval for the offshored and outsourced upstream manufacturing of its TrinScreen™ HIV rapid test. This approval is a significant milestone in the company’s transformation strategy aimed at improving financial performance and achieving sustainable profitability. The transition to outsourced production is expected to enhance gross margins, reduce fixed costs, and improve supply chain resilience, aligning with Trinity Biotech’s broader strategic goals of operational efficiency and market expansion.

Spark’s Take on TRIB Stock

According to Spark, TipRanks’ AI Analyst, TRIB is a Underperform.

Trinity Biotech’s stock score is low due to significant financial difficulties, including declining revenues and high leverage. Technical indicators suggest a downtrend with potential overbought conditions. Although the earnings call noted some improvements, persistent challenges and a negative valuation outlook weigh heavily on the overall score.

To see Spark’s full report on TRIB stock, click here.

More about Trinity Biotech

Trinity Biotech is a commercial-stage biotechnology company specializing in diabetes management solutions and human diagnostics, including wearable biosensors. The company develops, acquires, manufactures, and markets diagnostic systems for point-of-care and clinical laboratory segments, and has recently expanded into the wearable biosensor industry. Its products are used to detect infectious diseases and measure various blood chemistry parameters, with distribution in the United States and over 75 countries worldwide.

Average Trading Volume: 53,908

Technical Sentiment Signal: Sell

Current Market Cap: $10.56M

For an in-depth examination of TRIB stock, go to TipRanks’ Overview page.